Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) — The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a CAGR of 11.0% during the forecast period. The disorder is associated with melancholic clinical features, abnormal neural activity, bipolarity, inflammatory system activation, neurotransmitter dysfunction, and high traumatic load.
Fortune Business Insights™ mentioned this in a report titled “Treatment-Resistance Depression Treatment Market, 2023-2030.”
Notable Industry Development-
May 2022 – Compass Pathways presented positive Phase IIb study data of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans, the U.S.
Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/treatment-resistant-depression-treatment-market-102820
Key Takeaways:
- Treatment-resistant depression (TRD) occurs after inadequate response to around two antidepressants during the treatment process.
- The escalating prevalence of treatment-resistant depression stands out as a significant factor contributing to the market’s growth.
- In 2022, North America spearheaded the market, generating a revenue of USD 0.94 billion, and is poised to maintain its dominant position throughout the forecast period.
- The expansion can be attributed to the increasing healthcare expenditures and the growing prevalence of mood disorders.
List of Key Players Present in the Report:
Eli Lilly and Company (U.S.), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Janssen Global Services, LLC (Johnson & Johnson Services, Inc.) (Belgium), AbbVie Inc. (U.S.), AstraZeneca (U.K.), H. Lundbeck A/S (Denmark), Sandoz International GmbH (Novartis AG) (Germany), Par Pharmaceutical (Endo International plc) (India), Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) (Japan)
Report Scope:
| Report Coverage | Details |
| Forecast Period | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR | 11.0% |
| 2030 Value Projection | USD 4.06 Billion |
| Base Year | 2022 |
| Market Size in 2023 | USD 1.95 Billion |
| Historical Data | 2019 to 2021 |
| No. of Pages | 120 |
| Segments covered | By Drug Type, Distribution Channel, and Geography |
Browse Complete Report Details: https://www.fortunebusinessinsights.com/treatment-resistant-depression-treatment-market-102820
Segments-
Rising Demand for Antidepressant Drugs to Drive Segment Growth
By drug type, the treatment-resistant depression treatment market is segmented into N-methyl-D-aspartate (NMDA), antidepressants, antipsychotics, and others. The antidepressants segment is expected to hold the dominant market share during the forecast period. The growth is attributed to the increasing demand for antidepressant drugs due to the rising occurrence of treatment-resistant depression.
Rising Public Sector Investment in Healthcare Infrastructure to Drive Segment Growth
Based on distribution channel, the treatment-resistant depression treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2022 and is expected to grow at a significant CAGR during the forecast period. The growth is attributed to the increasing investment in healthcare infrastructure by the global public sector in emerging countries.
Geographically, the market is studied across North America, Europe, Asia Pacific, and Rest of the World.
By Drug Type
- N-methyl-D-aspartate (NMDA)
- Antidepressants
- Antipsychotics
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Geography
- North America (U.S. and Canada)
- Europe (Germany, U.K., France, Italy, Spain, and the Rest of Europe)
- Asia Pacific (China, India, Japan, Australia, and the Rest of Asia Pacific)
- Rest of the World
Quick Buy – Treatment-Resistant Depression Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102820
Drivers & Restraints-
Growing Prevalence of Treatment-Resistant Depression Worldwide to Drive Market Growth
One of the most important factors contributing to the treatment-resistant depression treatment market growth is the rise in the prevalence of this behavioral illness. TRD happens when a person hasn’t reacted to two separate antidepressants or has not taken them for a sufficient amount of time, typically six weeks. The demand for the disease’s therapy has increased as this medical condition’s prevalence has increased.
In addition to placing a tremendous burden on social and healthcare resources, the prevalence is linked to disproportionate healthcare costs with large direct and indirect costs, hampering market growth.
Regional Insights-
Growing Patient Population to Boost Market Growth in North America
North America accounted for USD 0.79 Billion in 2022 and is estimated to dominate the treatment-resistant depression treatment market during the forecast period. The growth is attributed to the rising patient population suffering from treatment-resistant depressive disorder in the region.
Europe held the second-largest treatment-resistant depression treatment market share in 2022. The European market will grow at a significant CAGR during the projected period due to the increasing launch of new drugs to treat the disorder in the region.
Competitive Landscape-
Important Business-related Announcements by Key Players to Influence Market Dynamics
Major treatment-resistant depression treatment players frequently announce significant business decisions that favor or negatively impact the market. Players buy businesses, introduce products, enter into collaboration agreements, and agree to terms with governmental bodies.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/treatment-resistant-depression-treatment-market-102820
FAQs
How big is the Treatment-Resistant Depression Treatment Market?
Treatment-Resistant Depression Treatment Market size is USD 1.95 billion in 2023.
How fast is the Treatment-Resistant Depression Treatment Market growing?
The Treatment-Resistant Depression Treatment Market will exhibit a CAGR of 11.0% during the forecast period, 2023-2030.
Related Reports:
Antidepressants Market Size, Share, Revenue Forecast and Opportunities
Anxiety Disorders and Depression Treatment Market Overview, Industry Share and Forecast
Antipsychotic Drugs Market Revenue, Size, Share, and Opportunities
Central Nervous System Treatment Market Size, Share, Opportunities & Analysis
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner – Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]
- Treatment-Resistant Depression Treatment Market